Vivek Subbiah, MD, emphasizes the need for improved guidance on practical toxicity management for various FGFR-altered malignancies, highlights best practices for monitoring and managing the most common on-target toxicities associated with FGFR inhibitors, and discusses the key implications of this review for those utilizing FGFR inhibitors.
Operator: Hello and welcome to the Incyte Second Quarter Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOMENTUM trial led by researchers at The University of Texas MD Anderson Cancer Center.
Momelotinib Yields Benefits for Myelofibrosis Patients miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
11.12.2022 - Incyte (Nasdaq:INCY) today announced new research detailing the development and mechanism of action of INCA033989, an Incyte-discovered, investigational novel anti-mutant calreticulin (CALR)-targeted monoclonal antibody. Pre-clinical data indicate . Seite 1